Metformin is the first-line drug for glycemic control, as it effectively reduces hepatic glucose production and improves insulin sensitivity in Type 2 diabetes mellitus in the clinic for more than five decades without stimulating insulin secretion, additional weight gain, or causing hypoglycemia [12-14]. The gene discussed is INS; the disease is Hypoglycemia.